Home NDC 60574-4113-1 Synagis
Product NDC 60574-4113
Requested package NDC 60574-4113-1
11-digit product format 605744113
Labeler code 60574
Product ID 60574-4113_14cf114d-3f1e-485b-83f3-61d88c3c1a98
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name palivizumab
Dosage form INJECTION, SOLUTION
Route INTRAMUSCULAR
Labeler MedImmune, LLC
Application BLA103770
Marketing category BLA
Marketing start 1998-06-19
Marketing end 0000-00-00
Substance PALIVIZUMAB
Active strength 100 mg/mL
Pharmacologic classes Antibodies, Monoclonal [CS],Fusion Protein Inhibitors [MoA],Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]
NDC exclude flag No
Listing certified through 2020-12-31
Current FDA listing Historical FDA.report record
Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 12 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Snapshot, Source SHA-256 table Captured / source date Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 f5e01cc5f278…a2eaf40c39c3…2025-04-01 02:39 UTC · source 2025-03-31 2ef7874e63bc…57b86245f4fa…2025-03-28 20:22 UTC · source 2025-03-28 a1b67e2a42f9…c4cf2c586c0d…2025-03-22 03:12 UTC · source 2025-03-21 cfe11265f3b6…090c488252e2…2025-03-10 12:48 UTC · source 2025-03-10 cdf11ea48f46…ba0047e9e063…2025-02-02 03:52 UTC · source 2025-01-31 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 0efc9e666f02…f202fb6c5f17…2024-11-09 02:27 UTC · source 2024-11-08 ad56d346431e…cc804d4bbf1e…2024-10-04 04:10 UTC · source 2024-10-03 367a005e9d99…383a685ebd0f…2024-07-10 04:00 UTC · source 2024-07-09 557ba5c1ecfa…9c80585c8c6e…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed Socrata Ingredients# Ingredient, Type, UNII table Ingredient Type UNII DailyMed label SPL version Uploaded PALIVIZUMAB ACTIVE INGREDIENT DQ448MW7KS SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [MEDIMMUNE, LLC] 28 PALIVIZUMAB ACTIVE MOIETY DQ448MW7KS SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [MEDIMMUNE, LLC] 28 CHLORIDE ION INACTIVE INGREDIENT Q32ZN48698 SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [MEDIMMUNE, LLC] 28 GLYCINE INACTIVE INGREDIENT TE7660XO1C SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [MEDIMMUNE, LLC] 28 HISTIDINE INACTIVE INGREDIENT 4QD397987E SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [MEDIMMUNE, LLC] 28
Purple Book Biologic Products# BLA, Proprietary name, Proper name table BLA Proprietary name Proper name License type Status Latest source 103770 Synagis palivizumab 351(a) Disc 2026-10-01
Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 60574-4113-1 60574411301 1 mL in 1 VIAL, SINGLE-DOSE (60574-4113-1) 1 ml 2005-09-28 0000-00-00 No No Current